Effectiveness of fluconazole for suppressive maintenance therapy in patients with RVVC: A randomized placebo-controlled study

Iranian Journal of Pharmaceutical Research

Volumn 8, Issue 4, 2009, Pages 307-313

  Bolouri, Forouzan ^a   Tabrizi, Nasrin Moghadami ^a   Tanha, Fatemeh Davari ^a   Niroomand, Nasrin ^a   Azmoodeh, Azra ^a   Emami, Saeed ^b   Falahati, Mehraban ^c   Sharifnia, Somaye ^c   Safavi, Maliheh ^d   Shafiee, Abbas ^d   Foroumadi, Alireza ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Fluconazole; Randomized clinical study; Recurrent vulvovaginal candidiasis (RVVC); Suppressive therapy

Indexed keywords

FLUCONAZOLE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT INFECTION; TREATMENT DURATION; VAGINA CANDIDIASIS;

EID: 76249134474     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Patel DA, Gillespie B, Sobel JD, Leaman D, Nyirjesy P, Weitz MV and Foxman B. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy: Results of a prospective cohort study. Am. J. Obstet. Gynecol. (2004) 190: 644-653.
2. Donders G, Bellen G, Byttebier G, Verguts L, Hinoul P, Walckiers R, Stalpaert M, Vereecken A and Eldere TV Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am. J. Obstet. Gynecol. (2008) 199: 613e1-613e9.
3. Rodgers CA and Beardall AJ. Recurrent vulvovaginal candidiasis: Why does it occur? Int. J. Std. AIDS (1999) 10: 435-441.
4. Stewart DE, Whelan CI, Fong IW and Tessler KM. Psychosocial aspects of chronic, clinically unconfirmed vulvovaginitis. Obstet. Gynecol. (1990) 76: 852-826.
5. Ray D, Goswami R, Banerjee U, Dadhwal V, Goswami D, Mandal P, Sreenivas V and Kochupillai N. Prevalence of Candida giabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. Diabetes Care (2007) 30: 312-317.
6. Fidel PL and Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin. Microbiol. Rev. (1996) 9: 335-348.
7. Sobel JD. Pathogenesis of recurrent vulvovaginal candidiasis. Curr Infect. Dis. Rep. (2002) 4: 514-519.
8. Kotarski J, Drews K, Maleszka R, Rechberger T, Woroń J and Tomaszewski J. Treatment of acute and recurrent vulvovaginal candidiasis (VVC/rVVC)-state of art in 2008. Ginekol. Pol. (2008) 79: 638-652.
9. Nurbhai M, Grimshaw J, Watson M, Bond C, Mollison J and Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush). Cochrane Database Syst. Rev. (2007) 17: CD002845.
10. Groll AH, Piscitelli SC and Walsh TJ. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. (1998) 44: 343-500.
11. Claney CJ and Nguyen MH. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. (1998) 17: 573-575.
12. Nagappan V and Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin. Infect. Dis. (2007) 45: 1610-1617.
13. Houang ET, Chappatte O, Byrne D, Macrae PV and Thospe JE. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob. Agents Chemother. (1990) 34: 909-910.
14. Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton T, Rompalo A, Sperling M, Livengood C, Horowitz B, Thron JV, Edwards L, Panzer H and Chu TC. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N. Engl. J. Med. (2004) 351: 876-883.
15. Sobel JD, Kapernick PS, Zervos M, Reed BD, Hooton T, Soper D, Nyirjesy P, Heine MW, Willems J, Panzer H and Wittes H. Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am. J. Obstet. Gynecol. (2001) 185: 363-369.
16. th Ed, Lippincott Williams & Wilkins, Philadelphia (2007) 547.
17. Patel HS, Peters MD and Smith CL. Is there a role for fluconazole in the treatment of vulvovaginal candidiasis? Ann. Pharmacother. (1992) 26: 350-353.
18. Ventolini G, Baggish MS and Walsh PM. vulvovaginal candidiasis from non-albicans species: retrospective study of recurrence rate after fluconazole therapy. J. Reprod. Med. (2006) 51: 475-478.
19. Moosa MYS, Sobel JD, Elhalis H, Du W and Akins RA. Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium. Antimicrob. Agents Chemother. (2004) 48: 161-167.
20. Sobel JD. Treatment of vaginal Candida infections. Expert Opin. Pharmacother. (2002) 3: 1059-1065.
21. Sobel JD. Limitations of antifungal agents in the treatment of Candida vaginitis: future challenges. Drug Resist. Update (1999) 2: 148-152.
22. Ringdahl EN. Treatment of recurrent vulvovaginal candidiasis. Am. Fam. Physician (2000) 61: 3 306-12.
23. Larsson PG and Platz-Christensen JJ. Enumeration of clue cells in rehydrated air-dried vaginal wet smears for the diagnosis of bacterial vaginosis. Obstet. Gynecol. (1990) 76: 727-730.
24. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). National guideline for the management of vulvovaginal candidiasis. Sex. Transm. Infect. (1999) 75: S19.
25. Mohanty S, Xess I, Hasan F, Kapil A,Mittal S and Tolosa JE. Prevalence & susceptibility to fiuconazole of Candida species causing vulvovaginitis. Indian J. Med. Res. (2007) 126: 216-219.
26. Horowitz JB. Mycotic vulvovaginitis: a broad review. Am. J. Obstet. Gynecol. (1991) 165: 1188-1192.
27. Sobel JD. Vulvovaginitis due to Candida glabrata. An emerging problem. Mycoses (1998) 41: 18-22.
28. Sojakova M, Liptajova D, Simonicova M, Borovsky M and Subik J. Vulvovaginal candidiasis and susceptibility of pathogens to antifungal agents. Cesk. Gynekol. (2003) 68: 24-29.
29. Foxman B, Barlow R, D'Arcy H, Gillespie B and Sobel JD. Candida vaginitis: self-reported incidence and associated costs. Sex. Transm. Dis. (2000) 27: 230-235.
30. Borisov I, Kolarov G, Bobcheva S and Ivanova A. Treatment of chronic recurrent vulvovaginal candidiasis with fluconazole (fungolon-Actavis). Akush. Ginekol. (Sofiia). (2005) 44: 17-20.
31. Sobel JD. Fluconazole maintenance therapy in recurrent vulvovaginal candidiasis. Int. J. Gynecol. Obstet. (1992) 37: 17-24.
32. Spinillo A, Colonna L, Piazzi G, Baltaro F, Monaco A and Ferrari A. Managing recurrent vulvovaginal candidiasis. Intermittent prevention with itraconazole. J. Reprod. Med. (1997) 42: 83-87.
33. Xu J and Hitchcock K. How should you treat Candida vaginitis in patients on antibiotics? J. Fam. Practice (2007) 56: 671-672.
34. Cernicka J and Subik J. Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int. J. Antimicrob. Agents (2006) 27: 403-408.
35. Cross EW, Perk S and Perlin DS. Cross-resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis. Microb. Drug Resist. (2000) 6: 155-161.
36. Kontoyiannis DP and Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet (2002) 359: 1135-1144.
37. Sobel JD, Zervos M, Reed BD, Hooton T, Soper D, Nyisjesy P, Heine MW, Willems J and Panzer H. Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications. Antimicrob. Agents Chemother. (2003) 47: 34-38.
38. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ and Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases, J. Clin. Microbiol. (2005) 43: 2155-2162.
39. Sobel JD, Booker D, Stein GE, Thomason JL, Wermeling DP, Bradley B and Weinstein L. Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Am. J. Obstet. Gynecol. (1995) 172: 1263-1268.
40. Emami S, Behdad M, Foroumadi A, Falahati M, Lotfali E and Sharifinia S. Design of conformationally constrained azole antifungals: efficient synthesis and antifungal activity of trans-3-imidazolyflavanones. Chem. Biol. Drug Des. (2009) 73: 388-395.